GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » J.Molner AS (OTSE:MOLNR) » Definitions » Growth Rank

J.Molner AS (OTSE:MOLNR) Growth Rank : 0 (As of Jun. 13, 2024)


View and export this data going back to 2022. Start your Free Trial

What is J.Molner AS Growth Rank?

J.Molner AS has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


J.Molner AS Growth Rank Related Terms

Thank you for viewing the detailed overview of J.Molner AS's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


J.Molner AS (OTSE:MOLNR) Business Description

Traded in Other Exchanges
N/A
Address
Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company. The company is engaged in research and development in the field of biotechnology. The activities of the Company are divided into two fields: 1) Chemistry analytical and development services for third parties; 2) Development of the Company's own line of generic pharmaceuticals.

J.Molner AS (OTSE:MOLNR) Headlines

No Headlines